Infants with cystic fibrosis (CF) who are infected with Pseudomonas aeruginosa in their first six months are at heightened risk of having impaired lung function by the time they are preschool age, a new study reports. The study also showed that lung function measurements and CT scan imaging in…

Infection with the environmental bacteria Achromobacter in children with cystic fibrosis (CF) is linked with poorer lung function and more pulmonary exacerbations, a study suggests. These findings highlight the need to identify Achromobacter infection promptly so that children can receive appropriate treatment.  “Our results may indicate that…

Specific immune cells called macrophages in cystic fibrosis (CF) are unable to kill the bacteria Burkholderia cenocepacia due to impairments in mitochondria, the cell’s powerhouses, a new mouse study says. The finding suggests that boosting mitochondria function could help resolve chronic infection in CF. The study “Defective immunometabolism…

BiomX has unveiled a platform designed for more rapid and efficient development of phage therapy, which the company is using to test potential treatments, including one for Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). According to a press release, the company expects results of a proof-of-concept…

People with cystic fibrosis (CF) are more frequently infected with oral Candida fungus and carry a higher number of fungi than healthy individuals, a study has found. All fungal species identified in the study’s CF patients were susceptible to currently available anti-fungal medications. The study, “Oral…

The antibiotic-resistant bacterium Stenotrophomonas maltophilia, a dangerous bacteria for people with lung diseases such as cystic fibrosis (CF), is widely spread around the world, with most strains carrying virulence and resistance genes, a large genetic study shows. The study, “The phylogenetic landscape and nosocomial spread of…

Different types of Staphylococcus aureus can be found persistently in the airways of cystic fibrosis (CF) patients, but this bacteria population is influenced by age and prior antibiotic treatment, a new study says. …

The U.S. Food and Drug Administration (FDA) has designated Vast Therapeutics’ BIOC11 a Qualified Infectious Disease Product (QIDP) for the treatment of people with cystic fibrosis (CF) who have chronic pulmonary infections due to Pseudomonas aeruginosa. The QIDP designation makes BIOC11 eligible for priority-review and fast-track statuses…

The inhaled formulation of broad-spectrum antibiotics such as imipenem/cilastatin is a useful alternative to treat chronic lung bacterial infections in children with cystic fibrosis (CF) because it causes fewer side effects, two case reports suggest. The study, “Use of inhaled imipenem/cilastatin in pediatric patients with cystic…

Using antibiotics to fully eliminate new methicillin-resistant Staphylococcus aureus (MRSA) airway infections appears more effective than waiting for the infection to pass naturally in patients with cystic fibrosis (CF), a study reports. In addition, this approach,…